Literature DB >> 32779747

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Jason H Karnes1,2, Allan E Rettie3, Andrew A Somogyi4, Rachel Huddart5, Alison E Fohner6,7, Christine M Formea8, Ming Ta Michael Lee9, Adrian Llerena10, Michelle Whirl-Carrillo5, Teri E Klein5,11, Elizabeth J Phillips12, Scott Mintzer13, Andrea Gaedigk14,15, Kelly E Caudle16, John T Callaghan17.   

Abstract

Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32779747      PMCID： PMC7831382          DOI： 10.1002/cpt.2008

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  35 in total

Review 1.  Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Authors:  Carolina Céspedes-Garro; Ingrid Fricke-Galindo; María Eugenia G Naranjo; Fernanda Rodrigues-Soares; Humberto Fariñas; Fernando de Andrés; Marisol López-López; Eva M Peñas-Lledó; Adrián LLerena
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-11-23       Impact factor: 4.481

2.  A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.

Authors:  Christine Lonjou; Nicolas Borot; Peggy Sekula; Neil Ledger; Laure Thomas; Sima Halevy; Luigi Naldi; Jan-Nico Bouwes-Bavinck; Alexis Sidoroff; Claudia de Toma; Martin Schumacher; Jean-Claude Roujeau; Alain Hovnanian; Maja Mockenhaupt
Journal:  Pharmacogenet Genomics       Date:  2008-02       Impact factor: 2.089

Review 3.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

4.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

Review 5.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

6.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 7.  PharmGKB summary: phenytoin pathway.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; J Steven Leeder; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

8.  CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.

Authors:  Silvia Vogl; Roman W Lutz; Gilbert Schönfelder; Werner K Lutz
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.

Authors:  Andrea Gaedigk; Magnus Ingelman-Sundberg; Neil A Miller; J Steven Leeder; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2017-11-14       Impact factor: 6.875

10.  A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events.

Authors:  Hua Fang; Xiequn Xu; Kulvinder Kaur; Matthew Dedek; Guang-Dan Zhu; Bae J Riley; Frank G Espin; Andria L Del Tredici; Tanya A Moreno
Journal:  Front Pharmacol       Date:  2019-03-26       Impact factor: 5.810
View more
  26 in total

Review 1.  Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN.

Authors:  Michele L Ramien; Danny Mansour; Neil H Shear
Journal:  Paediatr Drugs       Date:  2022-06-09       Impact factor: 3.022

Review 2.  Keeping pace with CYP2D6 haplotype discovery: innovative methods to assign function.

Authors:  Karen E Brown; Jack W Staples; Erica L Woodahl
Journal:  Pharmacogenomics       Date:  2022-01-27       Impact factor: 2.533

Review 3.  Genetic Findings as the Potential Basis of Personalized Pharmacotherapy in Phelan-McDermid Syndrome.

Authors:  Brianna Dyar; Erika Meaddough; Sara M Sarasua; Curtis Rogers; Katy Phelan; Luigi Boccuto
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

4.  A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension.

Authors:  James C Coons; Karryn Crisamore; Solomon Adams; Ashley Modany; Marc A Simon; Wenchen Zhao; Imam H Shaik; Raman Venkataramanan; Philip E Empey
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

Review 5.  Role of pharmacogenomics in T-cell hypersensitivity drug reactions.

Authors:  Rebecca J Hertzman; Pooja Deshpande; Andrew Gibson; Elizabeth J Phillips
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-08-01

Review 6.  PharmVar GeneFocus: CYP2C9.

Authors:  Katrin Sangkuhl; Karla Claudio-Campos; Larisa H Cavallari; Jose A G Agundez; Michelle Whirl-Carrillo; Jorge Duconge; Andria L Del Tredici; Mia Wadelius; Mariana Rodrigues Botton; Erica L Woodahl; Stuart A Scott; Teri E Klein; Victoria M Pratt; Ann K Daly; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-07-12       Impact factor: 6.903

Review 7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

Review 8.  Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.

Authors:  Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips
Journal:  Clin Pharmacol Ther       Date:  2021-07-17       Impact factor: 6.875

9.  Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Authors:  Pritmohinder S Gill; Feliciano B Yu; Patricia A Porter-Gill; Bobby L Boyanton; Judy C Allen; Jason E Farrar; Aravindhan Veerapandiyan; Parthak Prodhan; Kevin J Bielamowicz; Elizabeth Sellars; Andrew Burrow; Joshua L Kennedy; Jeffery L Clothier; David L Becton; Don Rule; G Bradley Schaefer
Journal:  J Pers Med       Date:  2021-05-11

10.  Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.

Authors:  Clara J Amorosi; Melissa A Chiasson; Matthew G McDonald; Lai Hong Wong; Katherine A Sitko; Gabriel Boyle; John P Kowalski; Allan E Rettie; Douglas M Fowler; Maitreya J Dunham
Journal:  Am J Hum Genet       Date:  2021-07-26       Impact factor: 11.025
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.